Identifying early signs of Alzheimer's disease and resilience factors
Official title: Novel Neurocognitive Markers of Risk for and Resilience to Cognitive Decline in Preclinical Alzheimer's Disease
Funded at Rhode Island Hospital · NIH-10861735 · Data updated 2026-11-12
This study is looking at new ways to spot early signs of Alzheimer's disease in older adults by examining brain activity, so we can help those at risk or who are doing well despite the challenges of aging.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rhode Island Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | August 15, 2020 |
| Project end | April 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $156,542 |
| NIH project number | 5K23AG065382-05 |
| Project ID | NIH-10861735 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are older adults who may be at risk for Alzheimer's disease or are experiencing early cognitive changes.
✕Less likely to help
Patients with advanced Alzheimer's disease or significant cognitive impairment may not benefit from this research.
What this research studies
This research investigates how to detect Alzheimer's disease (AD) in its earliest stages and identify individuals who may be at risk or show resilience to cognitive decline. The approach involves using advanced techniques like electroencephalography (EEG) to study brain activity in older adults. By analyzing brain network dynamics and understanding the functional neuroanatomy related to AD, the research aims to uncover novel predictors of cognitive decline. The project also includes training for the researcher to develop expertise in clinical research design and statistical analysis.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of Alzheimer's disease and better strategies for prevention and intervention.
How similar studies have gone: Previous research has shown promise in using EEG and neuroanatomical assessments to predict cognitive decline, indicating that this approach may yield valuable insights.
Where this research is happening
-
Rhode Island Hospital
Providence, United States Active
Researchers
- Principal investigator: Korthauer, Laura — Rhode Island Hospital
- Study coordinator: Korthauer, Laura
Related research
Other NIH-funded projects on the same topics.
-
Understanding resilience to Alzheimer's disease in Colombian families with genetic mutations
This study is looking at how specific genetic changes linked to early-onset Alzheimer's disease impact memory and thinking skills in people from Colombia, especially those with these mutations and their family members, to find out what helps some people stay mentally sharp despite the disease.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Genetic and single-cell study of Alzheimer’s risk and resilience
Researchers will study how genes and cell-level signals contribute to Alzheimer’s risk and resilience, using human brains and mouse models to find clues for therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.